{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T11:33:58Z","timestamp":1786793638026,"version":"build-2736575974"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Science Center, Poland","award":["2023\/07\/X\/NZ6\/01239"],"award-info":[{"award-number":["2023\/07\/X\/NZ6\/01239"]}]},{"DOI":"10.13039\/501100010621","name":"Medical University of Lublin","doi-asserted-by":"crossref","award":["GI16"],"award-info":[{"award-number":["GI16"]}],"id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Chronic lymphocytic leukemia (CLL) is characterized by immune dysfunctions driven by miRNA deregulation and the activation of immune checkpoint pathways, which contribute to disease progression and secondary immunodeficiency (SID). This study examines the interplay between miRNA expression profiles, Epstein-Barr virus (EBV) reactivation, and immune checkpoint pathways in the context of small intestine disease (SID) development in chronic lymphocytic leukemia (CLL). Patients were stratified into groups based on the presence of SID and EBV reactivation. Comprehensive analyses included miRNA profiling, EBV infection markers, and the expression of PD-1, PD-L1, CTLA-4, CD200, and CD86 on CD4\u2009+\u2009and CD8\u2009+\u2009T cells, as well as CD19\u2009+\u2009B cells. The results revealed significant suppression of tumor-suppressive miRNAs (e.g., miR-15a, miR-181a, and miR-29a) in the SID EBV\u2009+\u2009group, correlating with enhanced immunosuppression. The highest expression of exhaustion markers (PD-1, PD-L1, CTLA-4) and immunosuppressive molecules (CD200\/CD200R) was observed in the SID EBV\u207a group compared to all other groups, including SID EBV\u207b, which may reflect the enhanced mechanisms of immunosuppression and lymphocyte exhaustion accompanying EBV reactivation in the course of secondary immunodeficiencies. Correlation analyses underscored significant associations between miRNA levels, EBV reactivation markers, and immune checkpoint activation. These findings highlight the dual role of miRNA deregulation and immune checkpoint activation in the immunosuppressive microenvironment of CLL. The study underscores the diagnostic and therapeutic potential of miRNAs and immune checkpoints in managing SID and EBV-associated immune dysregulation in CLL.<\/jats:p>","DOI":"10.1038\/s41598-025-01572-4","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T12:59:40Z","timestamp":1747054780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["MicroRNA changes with macro potential contribute to secondary immunodeficiency in chronic lymphocytic leukemia during epstein barr virus reactivation"],"prefix":"10.1038","volume":"15","author":[{"given":"Paulina","family":"Mertowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Mertowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Grywalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"1572_CR1","doi-asserted-by":"crossref","unstructured":"Allard, D. et al. CD73 promotes chronic lymphocytic leukemia. Cancers 14, 3130 (2022).","DOI":"10.3390\/cancers14133130"},{"key":"1572_CR2","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.3390\/cancers13092112","volume":"13","author":"C Sordo-Bahamonde","year":"2021","unstructured":"Sordo-Bahamonde, C. et al. LAG-3 Blockade with relatlimab (BMS-986016) restores Anti-Leukemic responses in chronic lymphocytic leukemia. Cancers 13, 2112 (2021).","journal-title":"Cancers"},{"key":"1572_CR3","doi-asserted-by":"publisher","first-page":"e21167","DOI":"10.1097\/MD.0000000000021167","volume":"99","author":"A Ntsethe","year":"2020","unstructured":"Ntsethe, A., Dludla, P. V., Nyambuya, T. M., Ngcobo, S. R. & Nkambule, B. B. The impact of immune checkpoint inhibitors in patients with chronic lymphocytic leukemia (CLL): A protocol for a systematic review and meta-analysis of randomized controlled trials. Medicine 99, e21167 (2020).","journal-title":"Medicine"},{"key":"1572_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s40425-019-0710-1","volume":"7","author":"D Mahadevan","year":"2019","unstructured":"Mahadevan, D. et al. Phase I study of Samalizumab in chronic lymphocytic leukemia and multiple myeloma: Blockade of the immune checkpoint CD200. J. Immunother Cancer. 7, 227 (2019).","journal-title":"J. Immunother Cancer"},{"key":"1572_CR5","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s11912-022-01261-9","volume":"24","author":"D Rivera","year":"2022","unstructured":"Rivera, D. & Ferrajoli, A. Managing the risk of infection in chronic lymphocytic leukemia in the era of new therapies. Curr. Oncol. Rep. 24, 1003\u20131014 (2022).","journal-title":"Curr. Oncol. Rep."},{"key":"1572_CR6","doi-asserted-by":"publisher","first-page":"1062376","DOI":"10.3389\/fimmu.2023.1062376","volume":"14","author":"A Noto","year":"2023","unstructured":"Noto, A. et al. Should treatment of hypogammaglobulinemia with Immunoglobulin replacement therapy (IgRT) become standard of care in patients with chronic lymphocytic leukemia? Front. Immunol. 14, 1062376 (2023).","journal-title":"Front. Immunol."},{"key":"1572_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40425-018-0384-0","volume":"6","author":"A Hantel","year":"2018","unstructured":"Hantel, A., Gabster, B., Cheng, J. X., Golomb, H. & Gajewski, T. F. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab\u2009+\u2009nivolumab. J. Immunother Cancer. 6, 73 (2018).","journal-title":"J. Immunother Cancer"},{"key":"1572_CR8","doi-asserted-by":"publisher","first-page":"5184","DOI":"10.3390\/cancers15215184","volume":"15","author":"P Mertowska","year":"2023","unstructured":"Mertowska, P. et al. Immune checkpoint pathway expression in lymphocyte subpopulations in patients with common variable immunodeficiency and chronic lymphocytic leukemia. Cancers 15, 5184 (2023).","journal-title":"Cancers"},{"key":"1572_CR9","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","volume":"121","author":"JC Riches","year":"2013","unstructured":"Riches, J. C. et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 121, 1612\u20131621 (2013).","journal-title":"Blood"},{"key":"1572_CR10","doi-asserted-by":"publisher","first-page":"4631","DOI":"10.1182\/blood-2023-189755","volume":"142","author":"S Thangavadivel","year":"2023","unstructured":"Thangavadivel, S. et al. T cell dysfunction and exhaustion in patients with CLL: the impact of long term ibrutinib treatment. Blood 142, 4631 (2023).","journal-title":"Blood"},{"key":"1572_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1182\/blood-2015-01-622936","volume":"126","author":"F McClanahan","year":"2015","unstructured":"McClanahan, F. et al. PD-L1 checkpoint Blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. Blood 126, 203\u2013211 (2015).","journal-title":"Blood"},{"key":"1572_CR12","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1182\/blood.V120.21.2871.2871","volume":"120","author":"AE Rodr\u00edguez","year":"2012","unstructured":"Rodr\u00edguez, A. E. et al. Molecular characterization of chronic lymphocytic leukemia patients with a high number of losses in 13q14. Blood 120, 2871 (2012).","journal-title":"Blood"},{"key":"1572_CR13","doi-asserted-by":"publisher","first-page":"5201","DOI":"10.1182\/blood-2011-03-342436","volume":"118","author":"XJ Yan","year":"2011","unstructured":"Yan, X. J. et al. Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia. Blood 118, 5201\u20135210 (2011).","journal-title":"Blood"},{"key":"1572_CR14","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1590\/1806-9282.20220260","volume":"68","author":"M Khodashenas","year":"1992","unstructured":"Khodashenas, M. et al. Evaluation of cytokine levels as possible predicting elements in patients with chronic lymphocytic leukemia. Rev. Assoc. Med. Bras. 68, 1364\u20131368 (1992).","journal-title":"Rev. Assoc. Med. Bras."},{"key":"1572_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00277-016-2840-6","volume":"96","author":"AA Filip","year":"2017","unstructured":"Filip, A. A. et al. Expression of Circulating MiRNAs associated with lymphocyte differentiation and activation in CLL\u2014another piece in the puzzle. Ann. Hematol. 96, 33\u201350 (2017).","journal-title":"Ann. Hematol."},{"key":"1572_CR16","doi-asserted-by":"publisher","first-page":"e16956","DOI":"10.1371\/journal.pone.0016956","volume":"6","author":"S Li","year":"2011","unstructured":"Li, S. et al. MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. PLOS ONE. 6, e16956 (2011).","journal-title":"PLOS ONE"},{"key":"1572_CR17","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/2211-5463.12853","volume":"10","author":"J Huang","year":"2020","unstructured":"Huang, J. et al. MicroRNA-155-5p suppresses PD-L1 expression in lung adenocarcinoma. FEBS Open. Bio. 10, 1065\u20131071 (2020).","journal-title":"FEBS Open. Bio"},{"key":"1572_CR18","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1158\/1078-0432.CCR-13-2497","volume":"20","author":"M Negrini","year":"2014","unstructured":"Negrini, M. et al. MicroRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters. Clin. Cancer Res. 20, 4141\u20134153 (2014).","journal-title":"Clin. Cancer Res."},{"key":"1572_CR19","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1182\/blood-2014-03-559690","volume":"124","author":"B Cui","year":"2014","unstructured":"Cui, B. et al. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood 124, 546\u2013554 (2014).","journal-title":"Blood"},{"key":"1572_CR20","doi-asserted-by":"publisher","first-page":"20683","DOI":"10.1074\/jbc.M117.809053","volume":"292","author":"D Yee","year":"2017","unstructured":"Yee, D., Shah, K. M., Coles, M. C., Sharp, T. V. & Lagos, D. MicroRNA-155 induction via TNF-\u03b1 and IFN-\u03b3 suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells. J. Biol. Chem. 292, 20683\u201320693 (2017).","journal-title":"J. Biol. Chem."},{"key":"1572_CR21","doi-asserted-by":"publisher","first-page":"12471","DOI":"10.3390\/ijms241512471","volume":"24","author":"F Autore","year":"2023","unstructured":"Autore, F. et al. Role of MicroRNAs in chronic lymphocytic leukemia. Int. J. Mol. Sci. 24, 12471 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1572_CR22","doi-asserted-by":"publisher","first-page":"154363","DOI":"10.1016\/j.prp.2023.154363","volume":"243","author":"AS Doghish","year":"2023","unstructured":"Doghish, A. S. et al. MiRNAs as cornerstones in chronic lymphocytic leukemia pathogenesis and therapeutic resistance\u2013 an emphasis on the interaction of signaling pathways. Pathol. - Res. Pract. 243, 154363 (2023).","journal-title":"Pathol. - Res. Pract."},{"key":"1572_CR23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1053\/j.seminhematol.2024.03.001","volume":"61","author":"R Bayraktar","year":"2024","unstructured":"Bayraktar, R., Fontana, B., Calin, G. A. & Nemeth, K. MiRNA biology in chronic lymphocytic leukemia. Semin. Hematol. 61, 181\u2013193 (2024).","journal-title":"Semin. Hematol."},{"key":"1572_CR24","doi-asserted-by":"publisher","unstructured":"Mesaros, O. et al. Dysregulated microRNAs chronic lymphocytic leuk. Cureus 16(9), e68770. https:\/\/doi.org\/10.7759\/cureus.68770 (2024).","DOI":"10.7759\/cureus.68770"},{"key":"1572_CR25","doi-asserted-by":"publisher","first-page":"738915","DOI":"10.3389\/fimmu.2021.738915","volume":"12","author":"A Allegra","year":"2021","unstructured":"Allegra, A., Tonacci, A., Musolino, C., Pioggia, G. & Gangemi, S. Secondary immunodeficiency in hematological malignancies: focus on multiple myeloma and chronic lymphocytic leukemia. Front. Immunol. 12, 738915 (2021).","journal-title":"Front. Immunol."},{"key":"1572_CR26","doi-asserted-by":"publisher","first-page":"13822","DOI":"10.3390\/ijms232213822","volume":"23","author":"K Kousar","year":"2022","unstructured":"Kousar, K. et al. MiRNAs in regulation of tumor microenvironment, chemotherapy resistance, immunotherapy modulation and MiRNA therapeutics in Cancer. Int. J. Mol. Sci. 23, 13822 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1572_CR27","doi-asserted-by":"publisher","first-page":"640207","DOI":"10.3389\/fonc.2021.640207","volume":"11","author":"AKF Lo","year":"2021","unstructured":"Lo, A. K. F., Dawson, C. W., Lung, H. L., Wong, K. L. & Young, L. S. The role of EBV-Encoded LMP1 in the NPC tumor microenvironment: from function to therapy. Front. Oncol. 11, 640207 (2021).","journal-title":"Front. Oncol."},{"key":"1572_CR28","doi-asserted-by":"publisher","unstructured":"Iizasa, H., Kim, H., Kartika, A. V., Kanehiro, Y. & Yoshiyama, H. Role of viral and host MicroRNAs in immune regulation of Epstein-Barr Virus-Associated diseases. Front. Immunol. 11, 367. https:\/\/doi.org\/10.3389\/fimmu.2020.00367 (2020).","DOI":"10.3389\/fimmu.2020.00367"},{"key":"1572_CR29","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1128\/JVI.05901-11","volume":"86","author":"H Yu","year":"2012","unstructured":"Yu, H. et al. Epstein-Barr virus downregulates MicroRNA 203 through the oncoprotein latent membrane protein 1: a contribution to increased tumor incidence in epithelial cells. J. Virol. 86, 3088\u20133099 (2012).","journal-title":"J. Virol."},{"key":"1572_CR30","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.micinf.2011.07.007","volume":"13","author":"E Forte","year":"2011","unstructured":"Forte, E. & Luftig, M. A. The role of MicroRNAs in Epstein-Barr virus latency and lytic reactivation. Microbes Infect. 13, 1156\u20131167 (2011).","journal-title":"Microbes Infect."},{"key":"1572_CR31","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.3390\/cancers13215451","volume":"13","author":"L Wang","year":"2021","unstructured":"Wang, L. & Ning, S. New look of EBV LMP1 signaling landscape. Cancers (Basel). 13, 5451 (2021).","journal-title":"Cancers (Basel)"},{"key":"1572_CR32","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","volume":"18","author":"MR Green","year":"2012","unstructured":"Green, M. R. et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in hodgkin lymphomas and Post-transplant lymphoproliferative disorders: implications for targeted therapy. Clin. Cancer Res. 18, 1611\u20131618 (2012).","journal-title":"Clin. Cancer Res."},{"key":"1572_CR33","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1097\/PAS.0000000000001919","volume":"46","author":"A Kume","year":"2022","unstructured":"Kume, A. et al. PD-L1 expression in LMP1-positive cells of Epstein-Barr Virus-associated malignant lymphomas and lymphoproliferative disorders: A Single-cell resolution analysis with multiplex fluorescence immunohistochemistry and in situ hybridization. Am. J. Surg. Pathol. 46, 1386\u20131396 (2022).","journal-title":"Am. J. Surg. Pathol."},{"key":"1572_CR34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-015-0112-x","volume":"8","author":"V Balatti","year":"2015","unstructured":"Balatti, V., Pekarky, Y. & Croce, C. M. Role of MicroRNA in chronic lymphocytic leukemia onset and progression. J. Hematol. Oncol. 8, 12 (2015).","journal-title":"J. Hematol. Oncol."},{"key":"1572_CR35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/cdd.2014.87","volume":"22","author":"Y Pekarsky","year":"2015","unstructured":"Pekarsky, Y. & Croce, C. M. Role of miR-15\/16 in CLL. Cell. Death Differ. 22, 6\u201311 (2015).","journal-title":"Cell. Death Differ."},{"key":"1572_CR36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.genrep.2018.06.012","volume":"12","author":"M Ramaiah","year":"2018","unstructured":"Ramaiah, M. Functions and epigenetic aspects of miR-15\/16: possible future cancer therapeutics. Gene Rep. 12, 149\u2013164 (2018).","journal-title":"Gene Rep."},{"key":"1572_CR37","doi-asserted-by":"publisher","first-page":"106568","DOI":"10.1016\/j.phrs.2022.106568","volume":"187","author":"M Hashemi","year":"2023","unstructured":"Hashemi, M. et al. Pre-clinical and clinical importance of miR-21 in human cancers: tumorigenesis, therapy response, delivery approaches and targeting agents. Pharmacol. Res. 187, 106568 (2023).","journal-title":"Pharmacol. Res."},{"key":"1572_CR38","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.omtn.2020.03.003","volume":"20","author":"D Bautista-S\u00e1nchez","year":"2020","unstructured":"Bautista-S\u00e1nchez, D. et al. The promising role of miR-21 as a Cancer biomarker and its importance in RNA-Based therapeutics. Mol. Ther. Nucleic Acids. 20, 409\u2013420 (2020).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1572_CR39","doi-asserted-by":"publisher","first-page":"114453","DOI":"10.1016\/j.biopha.2023.114453","volume":"161","author":"SF Hosseini","year":"2023","unstructured":"Hosseini, S. F. et al. The importance of hsa-miR-28 in human malignancies. Biomed. Pharmacother. 161, 114453 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"1572_CR40","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1186\/s12885-018-4915-3","volume":"18","author":"YQ Yang","year":"2018","unstructured":"Yang, Y. Q. et al. NDRG2 mRNA levels and miR-28-5p and miR-650 activity in chronic lymphocytic leukemia. BMC Cancer. 18, 1009 (2018).","journal-title":"BMC Cancer"},{"key":"1572_CR41","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.31557\/APJCP.2023.24.7.2439","volume":"24","author":"S Aref","year":"2023","unstructured":"Aref, S., Tantawy, E., Aref, A., Agdar, M. E., Ayed, M. & M. & Prognostic value of plasma miR-29a evaluation in chronic lymphocytic leukemia patients. Asian Pac. J. Cancer Prev. 24, 2439\u20132444 (2023).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"1572_CR42","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.3389\/fonc.2020.01772","volume":"10","author":"Y Dai","year":"2020","unstructured":"Dai, Y. et al. miR-29a-5p regulates the proliferation, invasion, and migration of gliomas by targeting DHRS4. Front. Oncol. 10, 1772 (2020).","journal-title":"Front. Oncol."},{"key":"1572_CR43","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.7150\/jca.38449","volume":"11","author":"W Han","year":"2020","unstructured":"Han, W., Cui, H., Liang, J. & Su, X. Role of MicroRNA-30c in cancer progression. J. Cancer. 11, 2593\u20132601 (2020).","journal-title":"J. Cancer"},{"key":"1572_CR44","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.3892\/ol.2020.11835","volume":"20","author":"C Gao","year":"2020","unstructured":"Gao, C., Wei, J., Tang, T. & Huang, Z. Role of microRNA-33a in malignant cells. Oncol. Lett. 20, 2537\u20132556 (2020).","journal-title":"Oncol. Lett."},{"key":"1572_CR45","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/cmi.2017.164","volume":"16","author":"Y Zhu","year":"2019","unstructured":"Zhu, Y. et al. miR-125b-5p and miR-99a-5p downregulate human \u0393\u03b4 T-cell activation and cytotoxicity. Cell. Mol. Immunol. 16, 112\u2013125 (2019).","journal-title":"Cell. Mol. Immunol."},{"key":"1572_CR46","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1182\/blood-2012-03-415737","volume":"120","author":"E Tili","year":"2012","unstructured":"Tili, E. et al. The down-regulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state. Blood 120, 2631\u20132638 (2012).","journal-title":"Blood"},{"key":"1572_CR47","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.omtn.2016.11.003","volume":"6","author":"JY Pan","year":"2017","unstructured":"Pan, J. Y. et al. miR-134: A human Cancer suppressor?? Molecular therapy. - Nucleic Acids. 6, 140\u2013149 (2017).","journal-title":"- Nucleic Acids"},{"key":"1572_CR48","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/cells13010084","volume":"13","author":"W Huang","year":"2023","unstructured":"Huang, W., Paul, D., Calin, G. A. & Bayraktar, R. miR-142: A master regulator in hematological malignancies and therapeutic opportunities. Cells 13, 84 (2023).","journal-title":"Cells"},{"key":"1572_CR49","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.3390\/ijms21072578","volume":"21","author":"O Kooshkaki","year":"2020","unstructured":"Kooshkaki, O. et al. MiR-144: A new possible therapeutic target and diagnostic\/prognostic tool in cancers. Int. J. Mol. Sci. 21, 2578 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1572_CR50","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1182\/blood-2013-09-527234","volume":"124","author":"M Mraz","year":"2014","unstructured":"Mraz, M. et al. miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood 124, 84\u201395 (2014).","journal-title":"Blood"},{"key":"1572_CR51","doi-asserted-by":"crossref","unstructured":"Papageorgiou, S. G. et al. MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor Prognosis. Dis Markers. 2046545 (2017). (2017).","DOI":"10.1155\/2017\/2046545"},{"key":"1572_CR52","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3892\/ijo.2023.5556","volume":"63","author":"J Li","year":"2023","unstructured":"Li, J. et al. Role of miR-181a-5p in cancer (Review). Int. J. Oncol. 63, 108 (2023).","journal-title":"Int. J. Oncol."},{"key":"1572_CR53","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3892\/or.2017.5425","volume":"37","author":"X Lyu","year":"2017","unstructured":"Lyu, X. et al. miR-181a-5p, an inducer of Wnt-signaling, facilitates cell proliferation in acute lymphoblastic leukemia. Oncol. Rep. 37, 1469\u20131476 (2017).","journal-title":"Oncol. Rep."},{"key":"1572_CR54","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.omtn.2022.02.005","volume":"27","author":"MT Di Martino","year":"2022","unstructured":"Di Martino, M. T. et al. miR-221\/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review. Mol. Ther. Nucleic Acids. 27, 1191\u20131224 (2022).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1572_CR55","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3892\/mmr.2022.12581","volume":"25","author":"A Grenda","year":"2022","unstructured":"Grenda, A., Filip, A. A. & W\u0105sik-Szczepanek, E. Inside the chronic lymphocytic leukemia cell: MiRNA and chromosomal aberrations. Mol. Med. Rep. 25, 65 (2022).","journal-title":"Mol. Med. Rep."},{"key":"1572_CR56","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41598-023-50628-w","volume":"14","author":"N Saffari","year":"2024","unstructured":"Saffari, N., Rahgozar, S., Faraji, E. & Sahin, F. Plasma-derived Exosomal miR-326, a prognostic biomarker and novel candidate for treatment of drug resistant pediatric acute lymphoblastic leukemia. Sci. Rep. 14, 691 (2024).","journal-title":"Sci. Rep."},{"key":"1572_CR57","doi-asserted-by":"crossref","unstructured":"Shafieizadegan, S., Aberuyi, N. & Rahgozar, S. The molecular impact of miR-326 in acute lymphoblastic leukemia and its cross talk with P53. Ann. Hematol. 104, 2417\u20132427 (2025).","DOI":"10.1007\/s00277-024-06181-1"},{"key":"1572_CR58","doi-asserted-by":"publisher","first-page":"7711","DOI":"10.1021\/acsomega.1c00035","volume":"6","author":"A Ninawe","year":"2021","unstructured":"Ninawe, A. et al. miR-486-5p: A prognostic biomarker for chronic myeloid leukemia. ACS Omega. 6, 7711\u20137718 (2021).","journal-title":"ACS Omega"},{"key":"1572_CR59","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.mcp.2019.02.001","volume":"44","author":"H Liu","year":"2019","unstructured":"Liu, H., Ni, Z., Shi, L., Ma, L. & Zhao, J. MiR-486-5p inhibits the proliferation of leukemia cells and induces apoptosis through targeting FOXO1. Mol. Cell Probes. 44, 37\u201343 (2019).","journal-title":"Mol. Cell Probes"},{"key":"1572_CR60","doi-asserted-by":"crossref","unstructured":"Guo, B. et al. miR-744-5p Inhibits Multiple Myeloma Proliferation, Epithelial Mesenchymal Transformation and Glycolysis by Targeting SOX12\/Wnt\/\u03b2-Catenin Signaling.OTT 14, 1161\u20131172 (2021).<\\\/bib>","DOI":"10.2147\/OTT.S270636"},{"key":"1572_CR61","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/JBM.S230842","volume":"11","author":"E Farzadfard","year":"2020","unstructured":"Farzadfard, E., Kalantari, T. & Tamaddon, G. Serum expression of seven MicroRNAs in chronic lymphocytic leukemia patients. J. Blood Med. 11, 97\u2013102 (2020).","journal-title":"J. Blood Med."},{"key":"1572_CR62","doi-asserted-by":"publisher","first-page":"6505","DOI":"10.2147\/OTT.S150817","volume":"11","author":"E Grywalska","year":"2018","unstructured":"Grywalska, E., Pasiarski, M., G\u00f3\u017ad\u017a, S. & Roli\u0144ski, J. Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer. Onco Targets Ther. 11, 6505\u20136524 (2018).","journal-title":"Onco Targets Ther."},{"key":"1572_CR63","doi-asserted-by":"publisher","unstructured":"Landeira-Vi\u00f1uela, A. et al. Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: physiological immunomodulators or immune dysfunction. Front. Immunol. 13, 965905. https:\/\/doi.org\/10.3389\/fimmu.2022.965905 (2022).","DOI":"10.3389\/fimmu.2022.965905"},{"key":"1572_CR64","doi-asserted-by":"publisher","first-page":"5963","DOI":"10.3390\/cancers14235963","volume":"14","author":"Y Yang","year":"2022","unstructured":"Yang, Y., Zhang, W. & Lan, P. Immune checkpoint and other Receptor-Ligand pairs modulating macrophages in cancer: present and prospects. Cancers 14, 5963 (2022).","journal-title":"Cancers"},{"key":"1572_CR65","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13020-023-00785-x","volume":"18","author":"S Li","year":"2023","unstructured":"Li, S., Hao, L., Zhang, J., Deng, J. & Hu, X. Focus on T cell exhaustion: new advances in traditional Chinese medicine in infection and cancer. Chin. Med. 18, 76 (2023).","journal-title":"Chin. Med."},{"key":"1572_CR66","doi-asserted-by":"publisher","first-page":"iqad006","DOI":"10.1093\/oxfimm\/iqad006","volume":"4","author":"E Jenkins","year":"2023","unstructured":"Jenkins, E., Whitehead, T., Fellermeyer, M., Davis, S. J. & Sharma, S. The current state and future of T-cell exhaustion research. Oxf. Open. Immunol. 4, iqad006 (2023).","journal-title":"Oxf. Open. Immunol."},{"key":"1572_CR67","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/ejh.13223","volume":"102","author":"I Na","year":"2019","unstructured":"Na, I. et al. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies. Eur. J. Haematol. 102, 447\u2013456 (2019).","journal-title":"Eur. J. Haematol."},{"key":"1572_CR68","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1007\/s00277-024-05984-6","volume":"103","author":"C Siffel","year":"2024","unstructured":"Siffel, C. et al. Treatment patterns and burden of infection in patients with chronic lymphocytic leukemia and secondary immunodeficiency: a retrospective database study. Ann. Hematol. 103, 4567\u20134580 (2024).","journal-title":"Ann. Hematol."},{"key":"1572_CR69","doi-asserted-by":"publisher","first-page":"103896","DOI":"10.1016\/j.critrevonc.2022.103896","volume":"181","author":"N Shah","year":"2023","unstructured":"Shah, N., Mustafa, S. S. & Vinh, D. C. Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology. Crit. Rev. Oncol. Hematol. 181, 103896 (2023).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1572_CR70","first-page":"14","volume":"16","author":"O Yokus","year":"2022","unstructured":"Yokus, O., Jafarli, K., Sametoglu, F., Goze, H. & Serin, I. Secondary immunodeficiency frequency in patients with chronic lymphocytic leukemia: the relationship with stage and treatment. Int. J. Hematol. Oncol. Stem Cell. Res. 16, 14\u201321 (2022).","journal-title":"Int. J. Hematol. Oncol. Stem Cell. Res."},{"key":"1572_CR71","doi-asserted-by":"publisher","first-page":"101020","DOI":"10.1016\/j.blre.2022.101020","volume":"58","author":"S Jolles","year":"2023","unstructured":"Jolles, S. et al. Secondary antibody deficiency in chronic lymphocytic leukemia and non-Hodgkin lymphoma: recommendations from an international expert panel. Blood Rev. 58, 101020 (2023).","journal-title":"Blood Rev."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01572-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01572-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01572-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T12:02:40Z","timestamp":1750075360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01572-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1572"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-01572-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this Article was revised: The Funding section was omitted in the original version of this Article. It now accompanies the original Article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16446"}}